Our Focus on Immuno-Oncology

In the field of immuno-oncology, the STAM™ mouse is the most pathologically suitable model for developing new therapeutic drugs for liver cancer.

The utilization of STAM™ mouse enables non-clinical research for the development of liver cancer therapeutics targeting immune cells, tumor microenvironment, and genetic mutations.

READ MORE

NEWS RELEASE

Devonian Reports Positive Results in MASH Liver Study

In a great collaboration with Devonian Health Group Inc., we are happy to demonstrate preclinical proof of concept for Thykamine™ using our STAM (MASH-HCC model) mouse.   Thykamine™ treatment in STAM mice demonstrated improvements in NAS and fibrosis—key endpoints in clinical trials. Beyond atopic dermatitis and ulcerative colitis, Thykamine™ has also shown promising anti-inflammatory and…

READ MORE

EVENT

SMC will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology

We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology from May 9th (Thu) to 11th (Sat).   In the Exhibition section, we will introduce our drug efficacy evaluation study services using our original MASH (NASH)-hepatocarcinoma model, STAM™ mouse, as well as other…

READ MORE

New

Sig Transduct Target Ther.,

“The AKAP12-PKA axis regulates lipid homeostasis during alcohol-associated liver disease” (Signal Transduct Target Ther., DOI: 10.1038/s41392-025-02202-1, 2025)

READ MORE

STAM™ model

Our STAM™ model is a model that recapitulates the same disease progression as human MASH/HCC.

READ MORE

SERVICE

Search by topics

Our Patented original technologySTAM™ mouse

We are contributing to the world through providing cutting-edge non-clinical pharmacology studies with our unique patented technology, the STAM™ mouse. In order to develop a new drug, it is important to be able to accurately measure the effectiveness of the drug at the non-clinical trial stage. The STAM™ mouse, a model that more accurately reflects human pathology, plays a major role for this purpose.

LEARN MORE

COLUMN

2025.04.25

Liraglutide Evaluation in the CDAHFD Model

We would like to share with you our latest data obtained using the CDAHFD (Choline-Deficient, High-Fat Diet) mouse model, which rapidly reproduces key features of MASH, including steatosis, inflammation, and fibrosis. In this study, we evaluated the GLP-1 receptor agonist Liraglutide, and observed a clear anti-fibrotic effect in this model.   Overview of the CDAHFD Model Induced by a…

READ MORE

2025.04.18

Obese MASH model

We will introduce the obese MASH model in this article.   Existing MASH (metabolic dysfunction-associated steatohepatitis) models have different characteristics, such as obese/non-obese type, presence/absence of dyslipidemia, and differences regarding the capability to progression to HCC. Since MASH is a complex disease with diverse ways of pathogenesis, it is important to evaluate your test substance in multiple…

READ MORE

2025.04.11

Choosing the Right PSC Model for Your Research

In this article, we will introduce the key points for selecting a model that will lead to the success of your PSC research.   Ideal features of a PSC model:   ・Duct injury (intra- and extrahepatic) ・Ductular reaction ・Onion-like periductal fibrosis ・Portal inflammation ・Association with IBD             ▼ ▼ ▼  …

READ MORE

2025.04.04

【New Publication】Suppressing MASH Progression Using the STAM Mouse Model

A recent study using the STAM™ mouse model demonstrates clear efficacy in MASH progression inhibition – this could support your preclinical strategy.   ▶ Publication: Reactive Dicarbonyl Scavenging with 2-Hydroxybenzylamine Improves MASH   In this paper, the authors highlight the effect of 2-HOBA, a scavenger of reactive dicarbonyl electrophiles (DE), in improving MASH by reducing…

READ MORE

2025.03.28

Exploring New Therapeutic Potential of GPCRs: A Breakthrough in GPR119-Targeted NASH/MASH Treatment

Today, we are excited to share a recent study highlighting a promising approach to targeting G protein-coupled receptors (GPCRs) in NASH/MASH treatment.This study addresses a long-standing challenge in the development of NASH/MASH therapeutics using GPCR-targeting compounds. GPR119 activation has been shown to promote GLP-1 secretion and glucose-responsive insulin secretion, making it a compelling target for…

READ MORE

2025.03.21

SMC’s IPF study experience

Today, we would like to introduce our experience of the bleomycin-induced IPF study.   One of our most requested models, apart from our proprietary MASH model, is the bleomycin-induced IPF model for evaluations of drugs against lung fibrosis.   In the past 10 years, we have conducted over 150 studies using the bleomycin-induced IPF model and…

READ MORE

VIEW MORE

MODEL LINEUP

Introducing disease mice models related to inflammation, fibrosis, metabolic disorder, cancer, and cancer immunity, including the STAM™ mouse, the world's first MASH model mouse developed in our company.

STAM™ model

DISEASE AREAMASH/NASH-HCCTHERAPEUTIC AREAS

LEARN MORE

Bleomycin-induced pulmonary fibrosis model

DISEASE AREAIPFTHERAPEUTIC AREAS

LEARN MORE

Porcine Pancreatic Elastase (PPE) model

COPDDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

CCl4-induced liver fibrosis model

CirrhosisDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

Bile duct ligation (BDL) model

DISEASE AREAPBCTHERAPEUTIC AREAS

LEARN MORE

TAA-induced acute liver failure model

ALFDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

VIEW MORE

New stage

Our service and disease mouse models bridge the development of the next- Generation Cancer Therapies in the field of Immuno-oncology.

LEARN MORE

New stage

SMC Laboratories,Inc.

COMPANY

At SMC Laboratories, we support drug research with our cutting-edge non-clinical pharmacology studies to quickly deliver therapeutic drugs to patients suffering from diseases that cannot be treated with existing drugs.

LEARN MORE

PUBLICATION

We, SMC Laboratories, are highly regarded worldwide as a consulting – based CRO that designs tailored to the needs of pharmaceutical companies and research institutions.

NEWS

2025.03.04

NEWS RELEASE

Devonian Reports Positive Results in MASH Liver Study

In a great collaboration with Devonian Health Group Inc., we are happy to demonstrate preclinical proof of concept for Thykamine™ using our STAM (MASH-HCC model) mouse.   Thykamine™ treatment in STAM mice demonstrated improvements in NAS and fibrosis—key endpoints in clinical trials. Beyond atopic dermatitis and ulcerative colitis, Thykamine™ has also shown promising anti-inflammatory and…

READ MORE

2025.02.28

NEWS RELEASE

CytoDyn Reports Significant Fibrosis Reversal in SMC Lab Studies

In a great collaboration with CytoDyn Inc., we are pleased to share promising preclinical results demonstrating the efficacy of leronlimab (a CCR5 antagonist) in liver disease models. Using our STAM (MASH-HCC) and CCl₄-induced liver fibrosis models, leronlimab monotherapy successfully reversed liver fibrosis—an area with significant unmet medical need.   These findings suggest that leronlimab’s anti-fibrotic…

READ MORE

2024.12.27

Case study: Study published in Periodontitis promotes hepatocellular carcinoma Stelic Animal model mice.

We introduce a case study of basic research using our MASH model (STAM™ model).   It has been reported that periodontal disease may aggravate hepatocellular carcinoma, but the detailed mechanism behind this was unknown. To clarify the relationship between periodontal disease and hepatocellular carcinoma, the authors induced periodontitis in STAM™ mice and examined how it…

READ MORE

2024.12.09

CytoDyn has published a press release regarding the leronlimab efficacy preclinical study for MASH/fibrosis provided by SMC

CytoDyn Inc., which is our client, has announced the results of pharmacology study using a STAM™ mouse model. Resmetriom has been included in this pharmacology study, and its efficacy in treating fibrosis is directly compared with that of leronlimab.   For detail information, see the CytoDyn’s press release. CytoDyn Announces Preliminary Findings in Study with…

READ MORE

2024.11.28

Case study: Study published in Clinical and Translational Science on the effects of adiponectin-derived peptide ALY688 in MASH/liver fibrosis of STAM model.

We introduce a case study of pharmacology study of adiponectin-derived peptide ALY688 using our MASH model (STAM™ model).                 The adiponectin‐derived peptide ALY688 protects against the development of metabolic dysfunction‐associated steatohepatitis – Huang – 2024 – Clinical and Translational Science – Wiley Online Library   In this paper,…

READ MORE

2024.11.15

PUBLICATION

Our clients’ presentations at AASLD ~The Liver Meeting 2024 ~

Our clients presented data on treatment of MASH using STAMTM model at the AASLD ~The Liver Metting 2024~ (November 15-19).   For detailed information, see the below URL. aasld.org/sites/default/files/2024-10/1_the_liver_meeting_2024_abstracts.pdf   Poster #1060 The beneficial effect of resmetirom on tumorigenesis associated with MASH in STAM mice Institution: Kurume University School of Medicine (Japan)   Poster #1082 Impact…

READ MORE

VIEW MORE